KA
REGN icon

Klingman & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

Klingman & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$302K Buy
391
+9
+2% +$6.89K 0.01% 258
2025
Q4 		$295K Buy
+382
New +$259K 0.01% 257
2025
Q3 		– Sell
-382
Closed -$201K – 335
2025
Q2 		$201K Buy
+382
New +$213K 0.01% 310
2025
Q1 		– Sell
-291
Closed -$207K – 272
2024
Q4 		$207K Buy
291
+34
+13% +$28.5K 0.01% 248
2024
Q3 		$270K Buy
257
+4
+2% +$4.45K 0.02% 225
2024
Q2 		$266K Buy
253
+2
+0.8% +$1.94K 0.02% 207
2024
Q1 		$242K Buy
251
+4
+2% +$3.8K 0.02% 217
2023
Q4 		$217K Buy
247
+3
+1% +$2.47K 0.02% 217
2023
Q3 		$201K Buy
+244
New +$192K 0.02% 213

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Klingman & Associates's REGN Position: Q1 2026 in Review

Klingman & Associates increased its Regeneron Pharmaceuticals (REGN) stake by 2.4% in Q1 2026, buying an estimated $6.89K and bringing the position to 391 shares worth $302K. The position accounts for 0.01% of the portfolio, ranked #258.

Klingman & Associates first reported a position in REGN in Q3 2023 and has held it in 9 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Klingman & Associates held 391 shares of Regeneron Pharmaceuticals worth $302K as of Q1 2026.
  • Klingman & Associates bought 9 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $6.89K.
  • Regeneron Pharmaceuticals made up 0.01% of Klingman & Associates's portfolio in Q1 2026, its #258 holding.
  • Klingman & Associates first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 9 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Klingman & Associates's 13F filing for Q1 2026, filed 14 May 2026.